PPARA and cardiovascular disorder: The changes in plasma lipoprotein levels associatedwith treatment with PPAR agonists, characterized by decreased plasma TG levels,increased HDLc, and an increase in LDL size, are expected to decrease the riskfor cardiovascular disease.